Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Betahistine - Obecure

Drug Profile

Betahistine - Obecure

Alternative Names: Histalean; OBE 101

Latest Information Update: 18 Jul 2011

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Obecure
  • Class Pyridines; Small molecules
  • Mechanism of Action Histamine H1 receptor agonists; Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hyperlipidaemia; Obesity; Weight gain

Most Recent Events

  • 31 Dec 2010 Obecure completes a phase I trial in healthy volunteers in Romania [NCT01168336]
  • 26 Feb 2010 National Institutes of Health completes enrolment in its Phase-I trial (NCT00459992) for Obesity in USA
  • 17 Feb 2010 Grunenthal and Obecure Pharmaceuticals enter into an extension of their original strategic supply agreement
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top